HOME >> BIOLOGY >> NEWS
Removing prions that cause mad cow in humans from blood

East Hills, NY (February 8, 2005) - - Assessing the risk of potential exposure to variant Creutzfeldt-Jakob Disease (vCJD), the human form of 'mad cow disease,' from blood transfusion was the focus of the Food & Drug Administration (FDA) Transmissible Spongiform Encephalopathies (TSEs) Advisory Committee in Silver Spring, Maryland today. In response to the Committee's encouragement that new technologies should be considered that might lead to greater reduction of risk while not deferring many donors unnecessarily, Pall Corporation (NYSE: PLL) presented the latest scientific data on its new prion reduction technology. The Leukotrap Affinity Prion Reduction Filter, expected to be launched commercially in Europe this spring, removes infectious prions from red cells, the most widely transfused blood component. Prions are associated with causing vCJD and other fatal neurodegenerative diseases, known as TSEs.

Sam Coker PhD, Principal Scientist and Technical Director of Pall Medical, acknowledged the public health community's heightened concern about the possibility of a second wave of mad cow disease in humans of unknown magnitude globally, including North America. Japan is the latest nation to confirm a human case of mad cow disease.

The unknown time interval between exposure to the infected prion and onset of symptoms exacerbates the challenge of determining the size of a second wave or epidemic. This asymptomatic characteristic poses the key question: How many dormant carriers of vCJD are out there who are at risk of developing clinical disease and who also may be blood donors?

There is currently a ban on blood donations from people who lived in countries with bovine spongiform encephalopathy (BSE) infected cattle, which can have an impact on availability and result in shortages of lifesaving blood components. A loss of one percent of donors involves approximately 75,000 to 85,000 individuals in the first year, not to mention their future
'"/>

Contact: Marcia Katz
marcia_katz@pall.com
516-801-9128
Pall Corporation
8-Feb-2005


Page: 1 2 3 4

Related biology news :

1. Removing a hydrogen fuel-cell roadblock
2. Removing DNA repair gene causes metabolic syndrome
3. Removing egg from nest may help save endangered whooping crane
4. Alzheimers prevention role discovered for prions
5. Brittle prions are more infectious
6. Soil-bound prions that cause CWD remain infectious
7. Pall blood filtration technology removes prions that can cause TSEs
8. Deadly infectious entity of prions discovered
9. First technology to remove prions that cause vCJD from blood launched
10. Research confirms that vCJD prions can be removed from blood
11. Study begins to reveal clues to the cause and progression of sepsis

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/28/2016)... 28, 2016 First quarter 2016:   ... compared with the first quarter of 2015 The gross ... M (loss: 18.8) and the operating margin was 40% (-13) ... Cash flow from operations was SEK 249.9 M (21.2) , ... is unchanged, SEK 7,000-8,500 M. The operating margin for ...
(Date:4/15/2016)... April 15, 2016  A new partnership announced ... accurate underwriting decisions in a fraction of the ... priced and high-value life insurance policies to consumers ... With Force Diagnostics, rapid testing (A1C, Cotinine ... readings (blood pressure, weight, pulse, BMI, and activity ...
(Date:3/31/2016)...   LegacyXChange, Inc. ... LegacyXChange is excited to release its first ... be launched online site for trading 100% guaranteed authentic ... also provide potential shareholders a sense of the value ... industry that is notorious for fraud. The video is ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... ... June 23, 2016 , ... Supplyframe, the Industry Network for ... Design Lab . Located in Pasadena, Calif., the Design Lab’s mission is to ... are designed, built and brought to market. , The Design Lab is Supplyframe’s ...
(Date:6/23/2016)... 2016 Apellis Pharmaceuticals, Inc. today announced ... of its complement C3 inhibitor, APL-2. The trials ... dose studies designed to assess the safety, tolerability, ... in healthy adult volunteers. Forty subjects ... single dose (ranging from 45 to 1,440mg) or ...
(Date:6/23/2016)... NEW YORK , June 23, 2016 ... the trading session at 4,833.32, down 0.22%; the Dow Jones ... the S&P 500 closed at 2,085.45, down 0.17%. Stock-Callers.com has ... INFI ), Nektar Therapeutics (NASDAQ: NKTR ... BIND Therapeutics Inc. (NASDAQ: BIND ). Learn more ...
(Date:6/23/2016)... ... June 23, 2016 , ... Velocity Products, a division ... tuned and optimized exclusively for Okuma CNC machining centers at The International Manufacturing ... collaboration among several companies with expertise in toolholding, cutting tools, machining dynamics and ...
Breaking Biology Technology:
Cached News: